Dose and other factors associated with decreased pain intensity among patients initiating buprenorphine/naloxone

March 2, 2016

We examined dose and other factors associated with decreased pain intensity among patients initiating BUP/NX for OUD. (Source: Drug and Alcohol Dependence)

Read the full article →

ZUBSOLV (Buprenorphine Hydrochloride And Naloxone Hydrochloride) Tablet, Orally Disintegrating [Orexo US, Inc.]

March 2, 2016

Updated Date: Dec 24, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Read the full article →

Complete Care Medical Center Now Offering Same Week Appointments for…

March 2, 2016

One of the top outpatient Suboxone detox centers, Complete Care Medical Center, is now offering same week appointments with licensed specialists. The Center offers multiple licensed Suboxone doctors…(PRWeb December 28, 2014)Read the full story at http://www.prweb.com/releases/suboxone-doctor/fort-lauderdale-fl/prweb12416438.htm (Source: PRWeb: Medical Pharmaceuticals)

Read the full article →

Trends in the use of buprenorphine by office-based physicians in the United States, 2003-2013.

March 2, 2016

CONCLUSIONS: The use of buprenorphine products to treat opioid dependence has increased significantly in the past 10 years and has shifted to greater use by primary care physicians, indicating a rapidly changing face of opioid maintenance therapy in the United States. (Am J Addict 2015;24:24-29). PMID: 25823632 [PubMed – in process] (Source: The American Journal […]

Read the full article →

Geographic and Specialty Distribution of US Physicians Trained to Treat Opioid Use Disorder.

March 2, 2016

CONCLUSIONS: In the United States opioid use and related unintentional lethal overdoses continue to rise, particularly in rural areas. Increasing access to office-based treatment of opioid use disorder-particularly in rural America-is a promising strategy to address rising rates of opioid use disorder and unintentional lethal overdoses. PMID: 25583888 [PubMed – in process] (Source: Annals of […]

Read the full article →

Buprenorphine and Naloxone Compared With Methadone Treatment in Pregnancy.

March 2, 2016

CONCLUSION:: In a cohort of pregnant patients treated with either methadone or buprenorphine and naloxone in pregnancy, newborns exposed to maternal buprenorphine and naloxone had less frequent neonatal abstinence syndrome. Additionally, neonates exposed to buprenorphine and naloxone had shorter overall hospitalization lengths. LEVEL OF EVIDENCE:: II. PMID: 25569005 [PubMed – as supplied by publisher] (Source: […]

Read the full article →

Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent population.

March 2, 2016

CONCLUSIONS: Evaluating prescription opioid-dependent patients after 2 weeks of buprenorphine-naloxone treatment may help determine the likelihood of successful outcome at completion of the current treatment regimen. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00316277. PMID: 25562462 [PubMed – as supplied by publisher] (Source: Journal of Clinical Psychiatry)

Read the full article →

Pharmacokinetics of Sublingual Buprenorphine and Naloxone in Subjects with Mild to Severe Hepatic Impairment (Child-Pugh Classes A, B, and C), in Hepatitis C Virus-Seropositive Subjects, and in Healthy Volunteers

March 2, 2016

Conclusions Severe and moderate hepatic impairment significantly increased exposure of naloxone and to a lesser extent of buprenorphine. Therefore, buprenorphine/naloxone combination products should generally be avoided in patients with severe hepatic impairment and may not be appropriate for patients with moderate hepatic impairment. However, buprenorphine/naloxone products may be used with caution for maintenance treatment in […]

Read the full article →

Past-year gambling behaviour among patients receiving opioid substitution treatment

March 2, 2016

Conclusions: Gambling participation of the OST patients seemed to be somewhat similar compared with the Finnish general population, but gambling problems were more common among OST patients. Gender and age may not be very strong indicators of risk while screening problem gamblers among OST patients. Institution of a problem gambling screening program is recommended, and […]

Read the full article →

Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy

March 2, 2016

Conclusions There was no clinically meaningful impact of boceprevir on methadone or buprenorphine pharmacokinetics, suggesting that methadone/buprenorphine dose adjustments are not required upon coadministration with boceprevir. Individual patients may differ in their clinical experience and clinicians should maintain vigilance when coadministering these medications. (Source: European Journal of Clinical Pharmacology)

Read the full article →

← Previous Entries

Next Entries →